Show results for
drug-design-and-development Downloads
35 downloads found
With Novartis creating Borealis Biosciences and gaining approval for their IgAN therapy along with Travere Therapeutics, Otsuka’s success in phase III interim analysis, Apellis and Sobi’s phase III trial success, Judo Bio launching with $100M, Biogen acquiring HIBio for $1.15B, Vertex acquiring Alpine Immune Sciences for $4.9B and the FDA’s support of accelerated pathways for ...
High-throughput AhR-responsive cell-based reporter gene bioassay for rapid and sensitive identification and characterization of AhR ...
The MSR™ MicroSphere Refiner is a cGMP piece of equipment that allows drug developers and manufacturers to complete a wide range of aseptic processes with their microspheres at various scales. It is a one-of-its-kind solution has been developed and refined over decades following a Quality-by-Design (QbD) approach, taking into account the characteristics of microspheres and process behaviour. ...
Polymorphism, Salts & CrystallizationAn Integrated Approach to Solid-State Development Amazing where you can go-1-Introduction: Solid-State DevelopmentThe majority of drugs are administered as solids. ...
Looking to take your drug delivery to the next level? Celanese is your reliable partner to create novel, more effective drug delivery forms to optimize therapeutic outcomes and enhance patient experience. The clinically-proven VitalDose® technology platform provides a range of options for localized drug delivery through insert and implant formats across a variety of therapy areas. With our ...
BRIM Biotechnology applies integrated and efficient translational science to develop new treatments that help combat and cure disease. Our extensive experience and unique drug development engine, enables us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical ...
Over the last 30 years, technology and process advancements have allowed manufacturers to fill-finish a wider range of sterile liquids using BFS, including many biologics and vaccines, small molecules, and other sterile pharmaceuticals. At ApiJect, our engineers have taken these filling enhancements even further by developing proprietary temperature management methods that can potentially enable ...
Antibody therapeutic development is becoming faster and more data-driven. High-quality, accurate data is a key strategic asset for modern biopharma enterprises involved in biologic drug development. Lifesaving biologic drugs of the future will be delivered by companies that leverage ‘big data’ during the development process to minimize failures and increase success ...
“In 1981, I started my first job in a biomanufacturing company and I have spent the years since then developing processes and building facilities to speed molecules to the clinic and to market faster and with less risk. My early experiences gave me insights into the pains and pressure points when developing a drug and what is needed to succeed. Many of our scientists have a similar ...
ByCytiva
Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications for disease modelling and drug development, and potentially for ...
Diabetes has developed into one of the most serious health threats to the public throughout the world. A number of factors are reported to be associated with the exacerbation of diabetes. Creative Enzymes is devoted to supporting diabetes research and drug development in pharmaceuticals and institutes with our enzyme products. https://diagnostic-enzymes.creative-enzymes.com/diabetes.html ...
Gene Panel has been an invaluable tool to analyze parallel gene expression for disease-associated mutations. Here we present four powerful non-NGS technologies for gene panel that can promote your disease research, biomarker discovery, and targeted drug development. https://www.cd-genomics.com/diseasepanel/non-ngs-panel.html ...
A Clinical Stage/Life Sciences company focussed on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain ...
DIFICID is a macrolidc antibacterial indicated in adult and pediatric patients 6 months of age and older for the treatment of C. difficile-as&ocizicA diarrhea. (1.1). To reduce the development of drug-resistant bacteria and maintain the effectiveness ...
A Clinical Stage/Life Sciences company focussed on the drug discovery and development of next generation targeted therapeutics within the endocannabinoid system and specific brain ...
A Clinical Stage/Life Sciences company focussed on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain ...
The Disease Panel provides one-stop solutions (including both services and reagents) for the study of a wide range of diseases, including cancer, inherited disease, and infection by using NGS panels or non-NGS panels, which facilitate numerous applications such as disease research, biomarker discovery, and targeted drug development. https://www.cd-genomics.com/diseasepanel/custom-ngs-panel.html ...
A repurposed small molecule drug discovered from our SMART-ACT® platform, which has the potential to help develop drugs with well-established safety profiles in a time- and cost-effective ...
DIFICID is a macrolidc antibacterial indicated in adult and pediatric patients 6 months of age and older for the treatment of C. difficile-as&ocizicA diarrhea. 0.1). To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that arc proven or strongly suspected to be caused by ...
To the greatest extent, untargeted metabolomics reflects the multiple dynamic responses of living organisms to external stimuli, pathophysiological changes, and gene mutations in metabolite levels in vivo, offering a new perspective for disease diagnosis, pathological research, new drug development, drug toxicology, and other studies. ...